Trial Profile
A phase I/II open-label study of AMG-706 given orally in combination with standard concurrent chemoradiation regimen (cisplatin/etoposide/radiation) in stage IIIA/B non-small cell lung cancer (NSCLC)
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 11 May 2007
Price :
$35
*
At a glance
- Drugs Motesanib (Primary) ; Cisplatin; Etoposide
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 11 May 2007 New trial record.